| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 59 | 3.769 | 34.705 | 55.310 | 64.596 | 147.762 |
| Total Income - EUR | - | - | - | - | 59 | 4.088 | 34.705 | 55.310 | 64.618 | 147.814 |
| Total Expenses - EUR | - | - | - | - | 1.374 | 18.998 | 31.578 | 33.439 | 69.973 | 137.630 |
| Gross Profit/Loss - EUR | - | - | - | - | -1.315 | -14.910 | 3.127 | 21.871 | -5.355 | 10.184 |
| Net Profit/Loss - EUR | - | - | - | - | -1.316 | -14.948 | 2.610 | 20.799 | -5.872 | 5.972 |
| Employees | - | - | - | - | 2 | 2 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Treating To Cure S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 0 | 8.780 | 13.056 | 9.817 |
| Current Assets | - | - | - | - | 4.335 | 1.731 | 5.464 | 6.522 | 6.256 | 6.231 |
| Inventories | - | - | - | - | 3.897 | 68 | 0 | 0 | 0 | 73 |
| Receivables | - | - | - | - | 0 | 995 | 4.815 | 4.713 | 4.189 | 781 |
| Cash | - | - | - | - | 438 | 669 | 648 | 1.810 | 2.067 | 5.377 |
| Shareholders Funds | - | - | - | - | -1.274 | -16.198 | -13.229 | 7.530 | -3.373 | 1.963 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 5.609 | 17.929 | 18.692 | 7.773 | 22.685 | 17.318 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Treating To Cure S.r.l.